Diabetic kidney disease (DKD) is the major reason of chronic kidney disease (CKD)-caused end-stage renal failure (ESRF), and leads to high mortality worldwide. At present, the treatment of DKD is mainly focused on controlling the hyperglycemia, proteinuria, and hypertension, but is insufficient on the effective delay of DKD progression. *Cordyceps sinensis* is a kind of wild-used precious Chinese herb. Its extracts have effects of nephroprotection, hepatoprotection, neuroprotection, and protection against ischemia/reperfusion-induced injury, as well as anti-inflammatory and anti-oxidant activities. According to the theory of traditional Chinese medicine, *Cordyceps sinensis* can tonify the lung and the kidney. Several Chinese patent medicines produced from *Cordyceps sinensis* are often used to treat DKD and achieved considerable efficacy. This review summarized the clinical usage of *Cordyceps sinensis*, as well as its mainly biological activities including anti-hyperglycemic, anti-inflammatory, immunomodulatory, anti-oxidant, anti-fibrotic activities and regulation of apoptosis.

Keywords: *Cordyceps sinensis*, diabetic kidney disease, hyperglycemia, inflammation, oxidative stress

### INTRODUCTION

The prevalence of chronic kidney disease (CKD) is gradually increasing worldwide. If not treated timely, CKD may lead to heavy economic burden and poor prognosis by turning into end-stage renal failure (ESRF), which has no alternative treatment but renal replacement (Glasscock et al., 2017). Diabetic kidney disease (DKD) has become the major reason of CKD-caused ESRF. DKD occurs in approximately 30% of patients with type 1 diabetes mellitus (T1DM) and 40% of patients with type 2 diabetes mellitus (T2DM), and about 50% of cases are in developed countries (Tuttle et al., 2014; Alicic et al., 2017). Moreover, DKD is often associated with cardiovascular disease and causes high mortality. Therefore, early diagnosis and treatment of DKD are highly essential. Several medicines are demonstrated to mitigate the progress of DKD via reducing the proteinuria, such as the renin-angiotensin system (RAS) antagonists, sodium glucose co-transporter 2 (SGLT-2) inhibitors, the glucagon like peptide-1 (GLP-1) receptor agonists (Mayer et al., 2019; Saraﬁdis et al., 2019; An et al., 2021; Wheeler et al., 2021). However, applications of these agents can be limited by their adverse effects. For example, RAS antagonists may raise the risk of hyperkalemia and hypotension, and SGLT2 inhibitors might result in mycotic genital infections, diabetic ketoacidosis, and acute kidney injury in patients who have volume depletion or borderline arterial pressure (Fitchett, 2019; Lu et al., 2019).

Increasing studies have been conducted on the pathogenesis of DKD over the past years, and it has been demonstrated that inflammation, oxidative stress, apoptosis, and fibrosis play vital role in the
pathogenesis of DKD (Jha et al., 2016; Pichler et al., 2017; Xu et al., 2020). Applications of traditional Chinese medicine (TCM) in the treatment of DKD have become hot topics because of its advantage of muti-target therapy, which can reduce the side effects caused by other agents and increases efficacy. Based on it, TCM is used as an adjunctive treatment for DKD, improving the symptoms in patients with DKD, and alleviating the inflammation, oxidative stress, renal fibrosis, and so on (Ekor, 2014; Lu et al., 2019).

*Cordyceps sinensis* (BerK.) Sacc (*Figure 1*), also called *Cordyceps sinensis* (*C. sinensis*), is a kind of ascomycetes parasitic fungi which belongs to family *clavicipitaceae*, and it is mainly parasitic on insects and other arthropods (Olatunji et al., 2018). In China, *C. sinensis* is a precious Chinese herb with a medical history of hundreds of years. *C. sinensis* is first mentioned from *Ben Cao Bei Yao* (written by Wang Ang, tracing back to 1694AD). *C. sinensis* is wildly used in clinic, especially for nourishing the kidney and tonifying the lung. Furthermore, several medicinal preparations produced from *C. sinensis* are extensively used as auxiliary agents for the clinical treatment of DKD (Kai et al., 2015; Sheng et al., 2020). Nowadays, increasing researches have identified the bioactive ingredients in *C. sinensis* which can induce various effects on the treatment of DKD, such as anti-hyperglycemia, anti-inflammatory, anti-oxidant activities (Kiho et al., 1993; Shin et al., 2009b; El Zahraa Z El Ashry et al., 2012; Xiao et al., 2012). There are many mechanisms supporting the role of *C. sinensis* for the treatment of DKD. Therefore, keeping in view of the above facts, this review summarizes the recent studies pertaining to the chemical constituents, pharmacology, and toxicity of *C. sinensis*, and the biological activities of *C. sinensis* in DKD treatment to provide evidence for better clinical use of *C. sinensis*.

![Figure 1](image-url)  
*Cordycepin sinensis* in the soil (left), Traditional Chinese herb *Dong Chong Xia Cao* decoction pieces (right).

### 2.1 The Safety and Toxicity of *Cordyceps sinensis*

*C. sinensis* is widely used as the medicinal plant and health food. For the moment, there is still debate about whether we should worry about the toxicity of *C. sinensis*. The most prominent concern is about the accumulation of heavy metals, especially arsenic (As) in *C. sinensis* due to the impact of global environmental pollution. In 2016, it was warned by the National Medical Products Administration (NMPA) that long-term use of *C. sinensis* may lead to health risks, based on that total As in *C. sinensis* and its related products is 4.4–9.9 mg/kg (Li Y. et al., 2019a). However, As in *C. sinensis* is hard to be absorbed by human body (Liu et al., 2016). Besides, limited intake of *C. sinensis* cannot cause significant harm to human body (Zhou et al., 2018). Generally, the recommended dose of *C. sinensis* should not exceed 4 g per day and should not be used for more than 5 months per year (Li Y. et al., 2019a). Based on the existing studies, a clinical use of *C. sinensis* 3–6 g/day in patients with chronic renal failure was safe and could slow the progression of renal function (Zhu et al., 1998). Allen et al. found that daily taken 3.15 g of the synthetic compound of *C. sinensis* for 5 weeks had no additional adverse reactions compared with placebo (Parcell et al., 2004). Moreover, cultured *C. sinensis* has higher controllability on their growth environment, so it has certain advantages over natural *C. sinensis* in the control of heavy metal content, and Li et al. used the xanthine oxidase assay, the induction of hemolysis assay and the lipid peroxidation assay to confirm the strong anti-oxidant activity of both natural *C. sinensis* and cultured *Cordyceps mycelia* (Li et al., 2001), suggesting that natural *C. sinensis* can be replaced by cultured *C. sinensis* (Liu et al., 2016). So, *C. sinensis* is considered to be safe. In brief, the...
components are concluded in Table 1. The main active extracts in Cordyceps Sinensis. Table 1

| Classification | Constituent | Therapeutic Effect | Reference |
|----------------|------------|--------------------|-----------|
| Nucleosides    | Cordycepin | Anti-tumor, anti-inflammatory, anti-hyperglycemia, inhibition of platelet aggregation, hypolipidemic, analgesic, immunomodulatory, anti-inflammatory activities | Ashraf et al. (2020) |
|                | Adenosine  | Anti-convulsant, anti-inflammatory, inhibition of neurotransmitter release, modulation of adenylylate cyclase, immunomodulatory, cardioprotective activities | Shashidhar et al. (2013) |
|                | Guanosine  | Immunomodulatory effect | Kim, (2010) |
|                | Cordysin A-E | Cerebroprotective, superoxide anion inhibition, anti-inflammatory effects | Chen et al. (2013) |
| Polysaccharides | Exopolysaccharide fraction (EPSF) | Anti-tumor, anti-oxidant, anti-inflammatory, immunomodulatory activities | Zhang et al. (2005a) |
|                | Acid polysaccharide (APS) | Anti-oxidant, Immunomodulatory effects | Chen et al. (2010) |
|                | CPS-1 | Anti-oxidant, anti-inflammatory, immunomodulatory, metabolic regulation, nephroprotective, anti-hyperglycemia activities | Kwon et al. (2001) |
|                | CPS-2 | Cell proliferation inhibition, protection of chronic renal failure | Wang et al. (2014) |
| Sterols        | Ergosterol | Anti-tumor, cytotoxicity activities | Matsuda et al. (2009) |
|                | H1-A | Inhibit mesangial proliferation, regulation of apoptosis, immunomodulatory, reduce the production of anti-dsDNA | Yang et al. (2003) |
|                | β-sitosterol | Anti-tumor, anti-hyperglycemia, hypolipidemic, anti-arthritis, hepatoprotective activities | Ponnulakshmi et al. (2019) |
|                | Cerevisterol | Anti-inflammatory, anti-oxidant, anti-microbial, anti-hypoxia activities | Wang et al. (2019) |
|                | 5α,8α-epidioxy-24(R)-methylcholesta-6,22-dien-3β-D-glucopyranoside and 5α,6α-epoxy-24(R)-methylcholesta-7,22-dien-3β-ol | Anti-tumor | Chen et al. (2013) |
| Amino acids and Polypeptides | Cordymin | Anti-inflammatory, anti-nociceptive, using for diabetic osteopenia | Qian et al. (2012) |
|                | Cyclodipeptides A | Anti-malarial, cytotoxic activities | Jia et al. (2005) |
|                | Cordyceamides A and B | cytocidal activity | Jia et al. (2009) |

Toxicity of C. sinensis is controllable by rational intake and replacement by cultured ones.

**The Main Chemical Constituents and Pharmacology of Cordyceps sinensis**

A variety of C. sinensis derivatives have been applied to the clinic. The strains isolated from C. sinensis have been artificially cultivated and fermented into various products are in clinical use in China (Yang et al., 2018). There are 9 kinds of productions, among them, Jinshuibao capsule, Bailing capsule, and Zhiling capsule are wildly used to ameliorate the kidney function in patients with chronic renal failure, renal transplant and DKD (Tuli et al., 2014; Yoon et al., 2018; Ashraf et al., 2020). Many active components have been identified from C. sinensis, including cordycepin, adenosine, sterols, and many polysaccharides (Liu et al., 2015; Olatunji et al., 2018; Ashraf et al., 2020). The main biological effects of those active components are concluded in Table 1. Cordycepin (3′-deoxyadenosine) is considered as the most representative bioactive constituents and the marker of the quality of C. sinensis (Shashidhar et al., 2013). Cordycepin is a nucleoside analogue composed of a purine molecule linked to a ribose sugar, with a content ranged from 0.0076% to 0.029% (w/w) in C. sinensis (Hu et al., 2015). Cordycepin is involved in the process of transcription and activation of polymerases, exerting the anti-hyperglycemia, anti-inflammatory, and immunomodulatory effects via interfering in mTOR signal pathway, then repressing apoptosis and alleviating the kidney injury in DKD (Tuli et al., 2014; Yoon et al., 2018; Ashraf et al., 2020).

Adenosine is another main bioactive constituents of C. sinensis. The best-known effects of adenosine are anti-inflammatory and anti-convulsant activities (Shashidhar et al., 2013). Adenosine exerts biological effects and signal transduction via binding to adenosine receptors distributed on cell membranes, which are widely expressed in metabolic regulatory organs and kidney (Oyarzún et al., 2017). Adenosine plays a critical role in regulating glomerular perfusion pressure, filtration rate and renal tubular reabsorption, as well as influencing insulin secretion and

Frontiers in Pharmacology | www.frontiersin.org May 2022 | Volume 13 | Article 881835

3
regulating glucose homeostasis (Peleli and Carlstrom, 2017). Modulating adenosine receptor signal transduction is a new strategy for the treatment of DKD. Adenosine contributes to protecting DKD-related renal insufficiency by reducing the production of pro-inflammatory cytokines (e.g. TNF-α, IL-12, INF-γ) and increasing the expression of anti-inflammatory cytokines, such as IL-10 (Haskó et al., 1996). Although there is still ongoing research about its anti-oxidant activities. Previous study have shown that adenosine could prevent oxidative stress damage to cells by inducing an increase of glutathione peroxidase 1 (Zhang Y. et al., 2005b).

Polysaccharides are important and complex active components of *C. sinensis*, and the different types of polysaccharides separated from *C. sinensis* also have the activities of anti-inflammatory, anti-oxidant, metabolic regulation and so on (Paterson, 2008; Yan et al., 2014). CPS-1, a polysaccharide constituent detected in *C. sinensis*, is reported to have an insulin-like effect and promote the secretion of insulin, and it is expected to be developed as an agent to anti-diabetes (Kwon et al., 2001). Besides, various polysaccharides (such as EPS, CPS-F) exert anti-inflammatory and anti-oxidant activities via inhibiting the expression of pro-inflammatory cytokines, promoting the secretion of anti-inflammatory cytokines and scavenging free radicals to slow the progression of DKD (Wang et al., 2015; Li et al., 2020). In addition to focusing on a single component, it is also deemed that the effect of *C. sinensis* comes from a combination of various components. The anti-oxidant activity of *C. sinensis* may be related to the combined effects of polysaccharides, flavonoids, and polyphenols (also called the hydrogen-donating anti-oxidants) (Li et al., 2001; Yu et al., 2006). In order to clarify the mechanism of *C. sinensis*, further exploration is needed in the future.

3 THE BIOLOGICAL ACTIVITIES OF *CORDYCEPS SINENSIS* IN TREATING DIABETIC KIDNEY DISEASE

Persistent hyperglycemic environment enhances the protein glycation reaction, and increase of advanced glycation end products (AGEs), which can stimulate the production of reactive oxygen species (ROS) (Abou-Hany et al., 2018). Accumulated ROS induces oxidative stress and inflammation, meanwhile activates various signaling pathway, such as mitogen-activated protein kinases (MAPKs) and nuclear factor-κB (NF-κB) pathway, which in turn aggravates oxidative stress and inflammation (Tomás et al., 2002; Abou-Hany et al., 2018, Jia et al., 2018, Yan et al., 2020). Besides, excessive ROS could attack the unsaturated fatty acids in the biofilm phospholipid bilayer, causing lipid peroxidation and insulin resistance and then triggering multiple cascading reactions (Wei et al., 2019). The role of the signal mechanism in the treatment of DKD by *C. sinensis* will be discussed separately below.

3.1 Anti-Hyperglycemic Activity

The most important target for DKD treatment is to control hyperglycemia as early as possible. Long-term hyperglycemia is considered to be the main reason for abnormalities of tissue and microvascular. The role of *C. sinensis* in the treatment of DKD has been demonstrated (Luo et al., 2015). Jinshuibao capsule, a kind of *cordyceps* preparation, had additional beneficial effects on the DKD patients treated with angiotensin receptor blockers (ARB), and ameliorating the outcomes of patients (Cao et al., 2007). Several active constituents contribute to the anti-hyperglycemia activity. High fiber in the fruiting body of *C. sinensis* could improve glucose intake and insulin resistance of cells, which might due to its influence on glucose absorption (Lo et al., 2004). Moreover, polysaccharides are also the pivotal active constituents in anti-hyperglycemia. Polysaccharides-enriched extract could lower glycemic levels by 60–70% (Zhang et al., 2006). CS-F10, a polysaccharide derived from *C. sinensis* hot water extracts, significantly reduced the glucose levels both in normal and hyperglycemic mice by increasing the activity of glucokinase in livers (Kiho et al., 1999).

Besides, metabolic factors such as insulin levels and resistances may also be the central factors in DKD (Reidy et al., 2014). Insulin resistance can act on the glomerulus by mediating metabolism and hemodynamics, resulting in intraglomerular hypertension and thus influencing the progression of DKD (Karalliedde and Gnudi, 2016). Moreover, insulin resistance can also lead to the high salt-sensitivity, which associates with albuminuria and impairment of renal function, increasing the risk of macrovascular dysfunction (Karalliedde and Gnudi, 2016). Therefore, boosting insulin sensibility is imperative. It was shown that both the fermentation mycelia and the fermentation liquid of *C. sinensis* could significantly improve glucose response in OGTT and boost the insulin level in nicotinamide and streptozotocin (STZ)-induced diabetic rats (Lo et al., 2006). Several studies demonstrated that polysaccharides in *C. sinensis* could significantly decrease the blood glucose, and increase the insulin sensitivity in diabetic models (Kiho et al., 1993; Lo et al., 2006). In the state of insulin resistance, the impairment of insulin signaling in mesangial cells (MCs) might cause hypertrophy, proliferation, and matrix deposition of MCs (Artunc et al., 2016). Normally, relying on the actin cytoskeleton of podocytes, the glucose transporter 4 (GLUT4)-rich vesicles can be translocated, which helps the insulin-induced glucose uptake, while the destruction of insulin signaling leads to damage of the actin cytoskeleton, and the GLUT4 nuclear translocalization function is missing, eventually contributing to the loss of podocytes and the production of proteinuria (Coward et al., 2005; Artunc et al., 2016). β-sitosterol, an effective anti-oxidant and anti-hyperlipidemia plant sterol in *C. sinensis*, was reported to lower lipid levels, restore insulin sensitivity, and activate insulin receptors and GLUT4 in adipose tissue and eventually exert anti-hyperglycemia activity in diabetic rats (Ponnulakshmi et al., 2019). Cordycepin also plays a vital role in attenuating insulin resistance. It could improve insulin sensitivity by monitoring serum insulin levels and homeostasis model assessment of the insulin resistance index (Niu et al., 2010).

In addition, pathogenic oxygen free radicals caused by hyperglycemia play an important role in the pathogenesis of DKD (Śailaja Devi et al., 2000). CSP-1, a polysaccharide which
was separated from *C. sinensis*, had the effects of scavenging free radicals, and exerted anti-hyperglycemia effect via significantly decreasing the level of glucose by inducing the release of insulin in the remainder pancreatic cells and/or reducing the insulin metabolism (Li et al., 2006). The metabolic process of glucose involves various reactions and participations of cytokines. Among them, as an important endocrine organ, adipose tissue is closely related to inflammation and insulin resistance by secreting various hormones, pro- and anti-inflammatory adipokines, which can affect glucose, lipid metabolism and energy homeostasis (Snel et al., 2012). Patients with T2DM have more visceral subcutaneous fat than normal individuals, hyperglycemia causes macrophages in adipose tissue to secrete pro-inflammatory factors, and stimulates the accumulation of ectopic fat, so that the secretion of pro- and anti-inflammatory adipocytokines is imbalanced (Snel et al., 2012). The increase of pro-inflammatory adipocytokines, such as leptin, can aggravate inflammation via stimulating the secretion of inflammatory factors (TNF-α, IL-6, IL-12), and the increase of resistin reduces the anti-inflammatory effect of adiponectin, meantime inducing the aggravation of insulin resistance (Trig and Moschen, 2006). Using *C. sinensis* could significantly improve the insulin sensitivity and boost the expression of adiponectin within plasma and adipose tissue in STZ-induced diabetic mice (Huang et al., 2016). Thus, *C. sinensis* might become an effective adjuvant medicine in the treatment of DKD by its anti-hyperglycemic function and improving insulin resistance.

### 3.2 Anti-Inflammatory Activity

Chronic low-grade inflammation, also known as metaflammation, is a factor associated with the initiation and development of DKD. Metaflammation activates macrophages, and then secretes cytokines such as TNF-α, IL-1β to regulate immunity, afterwards the excessive activation of immune cells will also stimulate the inflammatory response (Li et al., 2020). There is a causal relationship between inflammation and insulin resistance, pro-inflammatory cytokines have been shown to mediate insulin resistance (Hotamisligil et al., 1995; Rotter et al., 2003). A meta-analysis suggested that *C. sinensis* combined with ACEI/ARB in patients with III to IV stage of DKD was effective to alleviate proteinuria, inflammation, and dyslipidemia by comparing 24-h proteinuria, urinary albumin excretion rate, microalbuminuria, serum creatinine, blood urea nitrogen, C-reactive protein, serum triglycerides, total cholesterol (Luo et al., 2015). Recent DKD studies have focused more on inflammation, thus studying the anti-inflammatory mechanisms of TCM has also provided a new perspective on treatment progress. The extracellular polysaccharides (EPS) extracted from *C. sinensis* mycelial fermentation could suppress the inflammatory NF-kB pathway by inhibiting the expression of pro-inflammatory cytokines TNF-α and iNOS, and improving the expression of the anti-inflammatory regulator IL-10 in LPS-induced mice models (Li et al., 2020).

NADPH oxidase (NOX) plays a prominent role in inflammation, and is one of the main sources of ROS in biological systems (Gorin and Wauquier, 2015). As one of the members of NOX family, NOX4 is highly expressed in kidney, and recently, NOX1 has also been found in kidney (Sedeek et al., 2013). Exposure to hyperglycemia, the expression of NOX4 in mouse proximal renal tubular cells is increased, using NOX1/4 inhibitors (GKT136901) or NOX4 siRNA could block the damage of hyperglycemia to kidney, and reduce the production of proteinuria (Sedeek et al., 2013). Cordycepin could reverse the albumin-induced epithelial-to-mesenchymal transition (EMT) in HK-2 cells via reducing the expression of Rac1, NOX4, p22phox, p47phox, and inhibiting the formation of ROS to alleviate inflammation and oxidative stress (Xiao et al., 2012). TNF and TNF receptor-1 (TNFR1) participate in the recruitment of NOX1, which is involved in inflammation, cell proliferation, and immune defense, the binding of TNF homotrimer to TNF-R1 initiates the binding of the adaptor protein, then recruits other effector proteins to form the TNF-R1 signaling complex, leading to the activation of multiple pathways, and then producing ROS to initiate inflammation (Chen and Goeddel, 2002; Kim et al., 2007). Based on a network pharmacological study, TNF is the crucial target in the treatment of DKD by *C. sinensis* (Li et al., 2021). And CPS-F, which was extracted from *C. sinensis*, could reduce the expression of pro-inflammatory cytokines and the production of ROS in human MCs by relying on TNF-R1, and inhibiting the activity of NOX1 to exert anti-inflammatory activity (Wang et al., 2015).

In recent years, it has been demonstrated that the activation of purinergic 2X7 receptor (P2X7R) and nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in podocytes are associated with the pathogenesis of DKD (Vonend et al., 2004; Shahzad et al., 2015). Robert et al. identified that P2X7R was highly expressed in renal biopsy specimens from patients with DKD, and the expression rate of glomerular P2X7R was about 50% (Menzies et al., 2017). The activation of P2X7R on M1 polarized pro-inflammatory macrophages, inducing the assembly of NLRP3 inflammasome, and then resulting in the release of pro-inflammatory factors and generation of inflammation (Olefsky and Glass, 2010). Therefore, antagonizing P2X7R may become a new type of anti-inflammatory therapy. Extensive evidence on *C. sinensis* involved improving DKD via inhibiting P2X7R/NLRP3 inflammasome axis activation. It could down-regulate the expression of P2X7R, and NLRP3 inflammasome (including NLRP3, ASC, caspase-1) in vivo and in vitro experiments, and the expression of downstream factors IL-1β and IL-18 was also significantly decreased, *C. sinensis* exerted an anti-inflammatory effect by antagonizing the P2X7R/NLRP3 inflammasome axis to relieve podocytes damage in DKD (Wang et al., 2018). *C. sinensis* can alleviate inflammation in various ways to delay the progression of DKD, and the active constituents contained in it are vital to the anti-inflammatory agents in the pipeline.

### 3.3 Immunomodulatory Activity on Macrophages

*C. sinensis* regulates immunomodulatory activity to improve DKD may be primarily concentrated on its polysaccharides and nucleoside components. The immunomodulatory effect of natural plant polysaccharides has been recognized (Yan et al.,...
The activation of macrophages is an important event in immune response, and the infiltration of macrophages is related to the progression of DKD to ESRF (Tang and Yiu, 2020). Plant polysaccharides can regulate the balance of pro- and anti-inflammatory cytokines secreted by macrophages to normalize the immunity (Müzes et al., 2012; Yin et al., 2019). Polysaccharides activate macrophages by binding to specific receptors on the surface of macrophages, then initiating a series of intracellular signaling cascade reactions. They exert immunomodulatory effects by regulating the production of ROS, secretion of cytokines and chemokines, cell proliferation and phagocytic activity of macrophages (Yin et al., 2019). Activated macrophages can be polarized into classically activated M1 and alternately activated M2 forms, where M2 cells have anti-inflammatory activity, abrogate the Th1 response, promote the Th2 response, release inflammatory substances, and promote epithelial and vascular repair (Belska et al., 2010; Wada and Makino, 2013). *C. sinensis* could promote macrophages polarize towards an M2 phenotype to inhibit the inflammatory response, and regulate the production of cytokines in RAW264.7 cells through the MAPK and PI3K/Akt signaling pathways, exerting immunomodulatory activity on macrophages (Liu et al., 2021). The balance of pro- and anti-inflammatory activities exerted by M1/M2 macrophages plays a pivotal role in the regulation of immune system (Mantovani et al., 2007), cordycepin and adenosine could alter the phenotypic conversion of macrophages by reducing the expression of pro-inflammatory factors and chemokines, such as IL-1β, IL-6, TNF-α, RANTES, CX3C11, and increasing the expression of anti-inflammatory cytokines, such as IL-1ra, IL-10, TGF-β (Shin et al., 2009b). By the way, the polarization of M2 macrophages can induce the occurrence of EMT and fibrosis, and M2 macrophages can promote the secretion of TGF-β, which is generally recognized as the typical pro-fibrosis factor and an anti-inflammatory factor (Zhu et al., 2017; Srivastava et al., 2019). *C. sinensis* up-regulated the mRNA levels of anti-inflammatory mediator (IL-10), and suppressed the mRNA levels of pro-inflammatory mediator (IL-1β) and the production of NO in LPS-induced RAW264.7 cells, regulating pro- and anti-inflammatory mediators to balance M1/M2 macrophages and avoiding excessive polarization of macrophages to exert immunomodulatory effect (Liu et al., 2021). It was demonstrated that cordycepin could inhibit the expression of TNF-α, IL-6, IL-1β, and mediate the immune responses in macrophages, decrease the expression of diabetes regulating genes (11β-HSD1, PPARy) in activated macrophages, finally play the immunomodulatory effect (Shin et al., 2009a). In summary, *C. sinensis* is closely linked to anti-inflammatory activity in regulating the immunity of macrophages. The *C. sinensis* preparations and their extracts are expected to become potential therapeutic agents for regulating metabolic inflammatory diseases.

Under the guidance of TCM theory, as a tonic, *C. sinensis* may also have a certain relationship with its regulation of T cells. The balance between effector T cells and regulatory T cells plays a regulatory role in the pathogenesis of DKD (Sabapathy et al., 2019). Lo et al. found that the polysaccharides extracted from the fermented mycelium of *C. sinensis* could increase the weight of the thymus gland in diabetic rats, and enhance the immunity (Lo et al., 2006). One study has reported that *C. sinensis* could regulate the ratio of CD4+CD25+FoxP3+ regulatory T (T reg) cells and Th17 cells in spleen and pancreatic lymph nodes of non-obese diabetic mice, thereby inhibiting DM (Shi et al., 2009). However, the regulation effect of *C. sinensis* on the balance of T cells in DKD is less, and further researches remain to be studied.

### 3.4 Anti-Oxidant Activity

Due to long-term exposure to high glucose environment, excessive amounts of superoxide, NO and other reactive oxygen substances are produced in cells, resulting in the decrease of endogenous and exogenous anti-oxidants, which cannot interact with ROS to counteract oxidative damage of cells (Di Vincenzo et al., 2019; Urner et al., 2020). The overproduction of ROS contributes to the microvascular damage, combines with oxidative stress, inducing the cellular apoptosis in DKD (Di Vincenzo et al., 2019). Hence, it is crucial to reduce the production of ROS by using anti-oxidant agents. It has been reported that *C. sinensis* has anti-oxidant effect (Dong and Yao, 2008). Fatma et al. found that *C. sinensis* could exert powerful anti-oxidant effect to significantly reduce the pancreatic malondialdehyde levels and increase the serum anti-oxidant property in vitro and in vivo experiments (El Zahraa Z El Ashry et al., 2012). And the anti-oxidant effect of *C. sinensis* might due to inhibit the production of ROS via the interference of *C. sinensis* extracts in ERK and Akt pathways (Wang et al., 2015).

ROS can induce the influence of unsaturated fatty acids, and then induce the occurrence of lipid peroxidation, subsequently resulting in a decrease in fluidity of podocytes membranes, eventually with consequent damage of the structures and functions of the cell membranes (Li et al., 2001; Su et al., 2019; Sidhom et al., 2021). The extracts of *C. sinensis* could attenuate lipid peroxidation and scavenge free radicals, while the enriched fraction of polysaccharides had even stronger anti-oxidant activity (Li et al., 2001). A current study indicated that the anti-oxidant activity of *C. sinensis* was achieved by melanin, it could scavenge DPPH and the chelating ability on ferrous ions (Dong and Yao, 2012). A study found that the phenols and flavonoids contained in Indian Himalayan isolate of *C. sinensis* (AECS) maybe the main components to exert anti-oxidant activity, AECS could significantly inhibit the release of TNF-α and IL-1β, and suppress the production of NO in LPS-induced THP1 cells (Rathor et al., 2014). Moreover, the rich unsaturated fatty acids in low-density lipoprotein (LDL) are susceptible to oxidative degeneration under cyclic oxidative conditions, and *C. sinensis* could reduce the occurrence of cardiovascular events in DKD by protecting the oxidation of LDL (Yu et al., 2006).

There were accumulating evidence demonstrated that excessive albumin could activate NOX via Rac1, thus stimulating the production of ROS, and overproduction of ROS and NOX maybe take part in EMT induced by albumin (Whaley-Connell et al., 2007; Xiao et al., 2012). Cordycepin could suppress oxidative stress damage and protect HK-2 cells by significantly inhibiting the expression of NADPH system constituent proteins, the production of ROS and the activity of NOX (Xiao et al., 2012). *C. sinensis* can scavenge free radicals and...
TABLE 2 | Major effects and targets of Cordyceps Sinensis in Diabetic Kidney Disease.

| Effects                        | Materials                  | Subjects                            | Targets                          | Reference                  |
|-------------------------------|----------------------------|-------------------------------------|----------------------------------|----------------------------|
| Anti-hyperglycemia effects    | CS-F10                     | STZ-induced and epinephrine-induced | GLUT2                            | Kho et al. (1999)          |
|                               | β-sitosterol               | high-fat diet and sucrose-induced   |                                  |                            |
|                               |                            | type-2 diabetic rats                |                                  |                            |
| Anti-inflammatory effect       | EPS                        | LPS-induced THP-1 cells, LPS-induced | NO, NF-κB, TNF-α, IL-10, IL-10, | Li et al. (2020)           |
|                               |                            | RAW264.7 cells, LPS-induced mice    | INOS                             |                            |
|                               | CPS-F                      | PDGF-BB induced HMCs                | ROS, TNF-α, TNF-R1, MCP-1, NOX1, | Wang et al. (2015)         |
| C. sinensis                   |                            | STZ-induced DKD rats, high-glucose  | P2X7R, NLRP3, ASC, caspase-1, IL-1β, | Wang et al. (2018)         |
|                               |                            | exposed podocytes                   | IL-18, nephrin, podocin, WT-1, desmin |                            |
| Cordycepin                    | Albinum-induced EMT in HK-2 | cells                               | E-cadherin, α-SMA, ROS, NOX4, p22phox, p47phox, Rac1-GTP | Xiao et al. (2012)          |
| Immunomodulatory effect       | Intracellular polysaccharides | LPS-induced RAW264.7 cells          | TNF-α, IL-β, IL-10, TGF-β1, INOS, NO, ERK, JNK, p38, Akt | Liu et al. (2021)          |
| C. sinensis                   |                            | IL-1β, IL-6, TNF-α, RANTES, CX3CL1, IL-1α, IL-10, TGF-β |                            |
| Cordycepin, adenosine         |                            | LPS-induced RAW264.7 cells          | E-cadherin, α-SMA, ROS, NOX4, P22phox, P47phox, Rac1-GTP | Shin et al. (2009b)         |
|                               | C. sinensis from India     | Non-obese diabetic mice             | CD4+CD25+FoxP3+ T reg cells, Th17 | Shin et al. (2009a)        |
|                               |                            | cells                               | NO, IL-1β, IL-6, TNF-α, 11β-HSD1, PPARγ, ICAM-1, B7-1/-1 |                            |
| Anti-oxidant effect           | CPS-F                      | PDGF-BB induced HMCs                | ROS, TNF-α, TNF-R1, MCP-1, NOX1, | Wang et al. (2015)         |
| C. sinensis                   |                            | STZ-induced THP1 cells              | TNF-α, IL-1β, NO                  | Rathor et al. (2014)       |
| Cordycepin                    | Albinum-induced EMT in HK-2| cells                               | E-cadherin, α-SMA, ROS, NOX4, P22phox, P47phox, Rac1-GTP | Xiao et al. (2012)          |
| Anti-fibrotic effect          | nucleoside/nucleobase-rich extract | STZ-induced diabetic mice, high-glucose exposed HK-2 cells | E-cadherin, α-SMA, FN, COL I, p38, ERK, JNK | Dong et al. (2019)         |
| C. sinensis                   | UUO rats                   |                                      |                                  | Du et al. (2015)           |
| C. sinensis                   | 5/6 subtotal nephrectomy rats |                                      | α-SMA, BAG3, TGF-β1, Smad2, Smad3, TβRI, TβRII, α-SMA, TGF-β1, Smad7 | Pan et al. (2013)          |
| Cordycepin                    | TGF-β1or BMP-4 induced NRK-52E cells/ MCMs, UUO mice |                                      |                                  | Gu et al. (2013)           |
| Cordycepin                    | TGF-β1 induced NRK-49F cells |                                      | α-SMA, FN, HGF, c-MET, TGF-β1, Smad2, Smad3, TβRI, Smad7 | Li et al. (2011)           |
| CPS-2                         | PDGF-BB induced HMCs       |                                      | α-SMA, PDGFβ1, TGF-β1, Smad3, ERK, TGFβRI | Wang et al. (2014)         |
| Regulation of apoptosis       | C. sinensis                | Ang II induced NRK-52E cells        |                                  | Tang et al. (2009)         |
| C. sinensis                   | HBx induced HK-2 cells     |                                      | KI, p65, p21, caspase-3           | He et al. (2012)           |
| H1-A                          | IL-1 and PDGF-BB induced HMCs |                                      | Capase-3, caspse-9, PI3K, Akt, Bax, Bcl-2 | Yang et al. (2003)         |

relieves the hyperactive oxidative systems in oxidative stress to protect the impaired kidney.

**Anti-Fibrotic Activity**

Renal interstitial fibrosis (RIF) is the ultimate outcome of DKD. The interaction of hemodynamic and metabolic factors leads to increased intraglomerular pressure and active vasoactive hormone pathway, which activates the secretion of proliferation and fibrosis-promoting cytokines, such as proinflammatory cytokine, TGF-β and the permeability enhancing growth factor, vascular endothelial growth factor (VEGF), ultimately leads to changes in kidney permeability and accumulation of extracellular matrix (ECM) and results in fibrosis (Zatz et al., 1986; Soldatos and Cooper, 2008). EMT plays an imperative role in the progress of fibrosis formation, and TGF-β is the key promoter of EMT. TGF-β induces the tubular epithelial cells turn into myofibroblasts, chronic inflammation, and leads to the production and accumulation of ECM (Gu et al., 2013; Kanasaki et al., 2013). At present, the anti-fibrotic treatment of C. sinensis mainly focused on regulating EMT and TGF-β. The nucleoside/nucleobase-rich extract from C. sinensis could significantly alleviate the development of DKD by inhibiting the progression of EMT and the accumulation of ECM via suppressing p38/ERK signaling pathway, together with decreased expression of fibrosis-related protein such as fibronectin and collagen I (Dong et al., 2019). Similarly, C. sinensis could mitigate the fibrosis by inhibiting the expression of Bcl-2-associated athanogene 3 (BAG3) and α-SMA in unilateral ureteral obstruction (UUO) rats, and regulating the formation of EMT (Du et al., 2015).

As an anti-inflammatory factor, TGF-β1 is also a typical profibrotic factor and involved in the TGF-β1/Smad signaling pathway, regulating the transcription of TGF-β1-reactive genes, interruption of any step in this cascading process may lead to the blocking of TGF-β signaling pathway, which leads to the blocking of myofibroblast activation (Wotton and Massagué, 2001). Hence, the agents for blockage TGF-β1/Smad signaling pathway is important to alleviate fibrosis. C. sinensis could exert anti-fibrotic activity by mediating TGF-β1/Smad signaling pathway, and attenuate renal fibrosis in 5/6 nephrectomy rats by abrogating the expression of TGF-β1, Smad2/3, TβRI, TβRII, p-Smad2/3, α-SMA, and FSP1, and upregulated Smad7 to inhibit EMT (Pan et al., 2013). As mentioned above, 3’d-deoxyadenosine, also known as cordycepin, was identified as the mainly anti-
fibrotic active biology constituent in *C. sinensis*, acting by interfering with profibrotic Smad signaling *in vitro* and *in vivo* (Gu et al., 2013). Another study indicated that cordycepin could effectively upregulate the anti-fibrosis factor hepatocyte growth factor (HGF) at both the gene and protein levels in NRK-49F cells to mediate the blockage of Smad2/3 transfer from cytoplasmic to the nucleus, and inhibited the conversion of quiescent interstitial fibroblasts into myofibroblasts by blocking the nuclear translocation of Smad2/3 (Li et al., 2011). CPS-2, a polysaccharide extracted from *C. sinensis* could inhibit the PDGF-BB-induced proliferation of MCs through PDGF/ERK and TGF-β1/Smad signaling pathway, and inhibit the expression of α-SMA, PDGFRβ, TGF-β1, and Smad3, exerting the nephroprotection (Wang et al., 2014). Reversing EMT is a treatment option, which can slow the process of fibrosis and prevent the progression of DKD to ESRF, and the active components of *C. sinensis*, including cordycepin, have an advantage in mitigating renal fibrosis, especially early intervention.

**Regulation of Apoptosis**

Apoptosis is one of the mechanisms of renal parenchymal cell reduction in the development of DKD, elimination of functional cells by apoptosis can induce renal insufficiency. In the progression of DKD, apoptosis can be induced by the increase of oxidative stress, and in the advanced DKD, with the progression of glomerular sclerosis, the number of apoptosis is increased and the renal function is gradually deteriorated (Sugiyama et al., 1996). It is indicated that *C. sinensis* can positively affect the homeostasis of apoptosis (Buenz et al., 2005), but the specific mechanism of regulating apoptosis in DKD remains to be explored. Klotho is a highly expressed anti-aging protein in kidney, which can inhibit oxidative stress by activating the Nrf2 signaling pathway, thereby protecting podocytes apoptosis in DKD (Xing et al., 2021). Capase-3 plays an important role in the process of apoptosis, and in the early stage of apoptosis, the activation of capase-3 can lyse the corresponding cytoplasmic nucleus substrate, eventually leading to apoptosis (Alnemri et al., 1996). TANG et al. demonstrated that the extracts of *C. sinensis* could suppress the apoptosis of NRK-52E cells by increasing the expression of Klotho, decreasing the expression of p53 and p21, and inhibiting the activation of capsase-3 (Tang et al., 2009). And *C. sinensis* had been shown could inhibit Hbx-induced apoptosis in HK-2 cells by suppressing the PI3K/Akt-Bcl-2 signaling cascades (He et al., 2020). Although it did not occur in DKD, the regulation of renal tubular epithelial cells apoptosis could still be used as a reference to lay the foundation for future research.

The pathological changes of DKD include mesangial proliferation, which is also an important reason for the increase of mesangial matrix and the abnormal synthesis and deposition of ECM (Lei et al., 2019). H1-A, a kind of polysaccharides extracted from *C. sinensis* was found to inhibit...
mesangial proliferation and protect MCs from cytolysis at high concentrations of DMSO, and possibly mediate the tyrosine phosphorylation of anti-apoptotic factors Bcl-2 and Bcl-XL to promote apoptosis (Yang et al., 2003). In contrast to inhibiting apoptosis in renal tubular epithelial cells, *C. sinensis* can promote apoptosis in MCs, which may be related to the pathology of DKD as thickening of the basement membrane and deposition of the mesangial matrix. Different cells have different pathological changes in the pathogenesis of DKD, and the effect of apoptosis has different meanings in different renal cells. In conclusion, it is necessary to continue to study the mechanism of *C. sinensis* regulating apoptosis in different renal intrinsic cells, and providing a new therapeutic target for the treatment of DKD.

**THE CLINICAL USE OF CORDYCEPS SINENSIS IN TREATING DIABETIC KIDNEY DISEASE**

At present, three major cordyceps preparations, Bailing capsule (BLC), Zhiling capsule (ZLC), and Jinshuibao capsule (JSBC) has been approved for clinical treatment of DKD in China (Luo et al., 2015).

Additional application of all three cordyceps preparations have been beneficial in treatment of DKD. Clinical studies have found that the combination of cordyceps preparations (BLC) with ACEI/ARB or SGLT2 inhibitors could significantly reduce the excretion of urinary protein, alleviate kidney damage, and delay the progression of DKD compared with the use of ACEI/ARB or SGLT2 inhibitors alone (Li Z. et al., 2019b; Li and Gao, 2021). In addition to improving kidney function, some scholars have made research on cordyceps preparations in improving inflammation, oxidative stress, and immune regulation of DKD patients. A previous study has shown that BLC was able to inhibit aldose reductase (AR), thereby inhibiting the polyl pathway in DKD (Luo et al., 2015). Specifically, Li et al. used BLC combined with dapaglirozin to treat patients with DKD for 12 weeks, the renal function indicators in the combination treatment group were significantly better than dapaglirozin alone, and the ocular vascular lesions of DKD patients were also alleviated (Li and Gao, 2021). Li et al. indicated that compared with the use of irbesartan alone, combined with BLC could significantly improve the micro-inflammatory state and oxidative stress response of DKD patients, with reduce levels of TNF-α, CRP, ROS and advanced protein oxidation product (AOPPS), and increased CD4+ and CD4+/CD8+ levels to regulate immune disorders (Li Z. et al., 2019b). JSBC combined with ACEI/ARB could effectively raise the total effective rate, reduce the 24 h urinary protein (24 h-UTP), urinary protein excretion rate and serum creatinine (Scr), and regulate glycolipid metabolism, the common using dose was from 3 to 6 capsules three times daily based on age (Li and Xu, 2020). The combination of JSBC and irbesartan could also effectively reduce endothelin-1 (ET-1), IL-6, TNF-α levels, and increase the expression of NO to improve vascular endothelial function and alleviate micro-inflammatory state in patients with DKD (Wu et al., 2019).

Similarly, ZLC combined with telmisartan could significantly reduce the levels of Scr, 24 h-UTP, TNF-α, CRP, IL-6 and ET, increase NO levels, improve glomerular vasomotor function, and delay the progression of DKD (Wang and Qi, 2018). At present, relevant studies have not found adverse reactions to the prolonged use of cordyceps preparations (Sheng et al., 2020), but it still needs to be supported by more high-quality randomized controlled trials. And there is a lack of high-quality evidence on the occurrence of cardiovascular events associated with DKD (Li and Xu, 2020; Sheng et al., 2020).

Some researched aimed to compare the differences of three major cordyceps preparations. JSBC, BLC and ZLC are prepared by the fermentation of Paecilomyces hepiali (strain Cs-4), Hirsutella sinensis (strain Cs-C-Q80) and Mortierella SP, and 64, 39, and 56 components were identified in the essential oils of JSBC, BLC, and ZLC, respectively (Zhang et al., 2017). 5,6-Dihydro-6-pentyl-2H-pyran-2-one (massoia lactone) was the main component in the volatiles of JSBC, and pyrazinamide was characteristic in BLC. Besides, ZLC had the highest proportion of fatty acid compounds up to 27.1%, which could effectively enhance cell function and improved the metabolic capacity of cells (Zhang et al., 2017; Song et al., 2018). Meantime, the analysis of nucleosides and bases in fermented cordyceps preparations found that the content of guanosine, uridine and adenosine in ZLC was comparable, and it was higher than that in BLC and JSBC, while the 3 bases in BLC were the lowest (Zhang et al., 2009). However, in spite of the differences between compositions of 3 cordyceps preparations, no clinical studies are comparing the efficacy of the three preparations in the treatment of DKD, and whether there are different effects between them is still worth exploring. The differently using conditions of the 3 cordyceps preparations remain one of the problems that need to be explored in clinical and future experimental studies. It is worth exploring the conditions among the three preparations which are applied to DKD and whether there are differences between their effects, in order to facilitate the best application in clinic.

**CONCLUSION**

At present, the clinical treatment of CKD is focused on symptomatic treatment. The first-line treatments are mainly based on RAS blockers. However, there will be rising limitations in the use of drugs with the decline of renal function until it turns into ESRF. The emergence of Chinese herbal medicines and various Chinese patent medicines as the adjuvant drugs can effectively alleviate the side effects of drugs and slow the progression of kidney function. This review focused on mechanisms of *C. sinensis* and its extracts in the treatment of DKD (Table 2, Figure 2). Clinical applications and its efficacy of Chinese patent medicines made from *C. sinensis* in treatment of DKD were also reviewed.

However, some important problems should be further investigated. For example, in the regulation of apoptosis of *C. sinensis*, why different regulatory effects on different renal
parenchymal cells remain to be explored. And the dose control of the extracted *C. sinensis* active substance should also be studied with a view to selecting the optimal clinical therapeutic dose. Moreover, the poly-component and multi-target effect of TCM is a double-edged sword. Although several main active ingredients, such as cordycepin, adenosine, and various polysaccharides, had been identified, there are still many components with unclear effects and functions. Therefore, it is suggested that we should continue to explore the potential active components and therapeutic effects of *C. sinensis* in the future. Pharmacological research on its main active extracts to candidate new agents and therapeutic targets are also imperative for its multiple applications in the clinic. Besides, considering the high prices of *C. sinensis*, more investigations are needed to reduce the economic burden on patients, including but not limited to artificial cultivation and development of new extraction methods. In addition, whether there are different effects among them still unclear and more research should be done to find the best conditions for each *cordyceps* preparation. High-quality prospective clinical trials with follow-up are also needed to provide convincing evidence of its safety and efficacy. We think that these explorations will provide new insight into clinical application of *C. sinensis* in treatment of DKD.

**AUTHOR CONTRIBUTIONS**

WL collected related studies and drafted the manuscript. YG, YZ, FY and XL collected related studies. NZ was responsible for the final review of the manuscript. All authors read and approved the final manuscript.

**FUNDING**

The study was supported by the National Natural Science Foundation of China (NO. 81973801); Capital’s Funds for Health Improvement and Research (NO. 2018-1-4161); Science and Technology Innovation Project of China Academy of Chinese Medical Sciences (NO. CI2021A01609).

**REFERENCES**

Abou-Hany, H. O., Atef, H., Said, E., Elkashef, H. A., and Salem, H. A. (2018). Cricrin Mediated Amelioration of Oxidative Burden and Inflammatory Cascade Suppresses Diabetic Nephropathy Progression in Diabetic Rats. *Chemico-biol. interactions* 284, 90–100. doi:10.1016/j.cbi.2018.02.001

Alicic, R. Z., Rooney, M. T., and Tuttle, K. R. (2017). Diabetic Kidney Disease: Challenges, Progress, and Possibilities. *Clin. J. Am. Soc. Nephrol.* 12, 2032–2045. doi:10.2215/CJN.11491116

Almenri, E. S., Livingston, D. J., Nicholson, D. W., Salvesen, G., Thornberry, N. A., Wong, W. W., et al. (1996). Human ICE/ED-3 Protease Nomenclature. *Cell*. 87, 171. doi:10.1016/0092-8674(96)81334-3

An, J., Niu, F., and Sim, J. J. (2021). Cardiovascular and Kidney Outcomes of Spiroolactone or Eplerenone in Combination with ACEI/ARBs in Patients with Diabetic Kidney Disease. *Pharmacotherapy* 41, 998–1008. doi:10.1002/phar.2633

Artunc, F., Schleicher, E., Weigert, C., Fritzsche, A., Stefan, N., and Häring, H. U. (2016). The Impact of Insulin Resistance on the Kidney and Vasculature. *Nat. Rev. Nephrol.* 12, 721–737. doi:10.1038/nrneph.2016.145

Ashraf, S. A., Elkhalfa, A. E. O., Siddiqui, A. J., Patel, M., Awadelkareem, A. M., Snoussi, M., et al. (2020). Cordycepin for Health and Wellbeing: A Potent Bioactive Metabolite of an Entomopathogenic Cordyceps Medicinal Fungus and its Nutraceutical and Therapeutic Potential. *Molecules* 25, 2735. doi:10.3390/molecules25122735

Belska, N. V., Guriev, A. M., Danilets, M. G., Trophinovna, E. S., Uchasova, E. G., Ligatcheva, A. A., et al. (2010). Water-soluble Polysaccharide Obtained from Acorus calamus L. Classically Activates Macrophages and Stimulates Th1 Response. *Int. Immunopharmacol.* 10, 933–942. doi:10.1016/j.intimp.2010.05.005

Buenz, E. J., Bauer, B. A., Osmundson, T. W., and Motley, T. J. (2005). The Traditional Chinese Medicine Cordyceps Sinensis and its Effects on Apoptotic Homeostasis. *J. Ethnopharmacol.* 96, 19–29. doi:10.1016/j.jep.2004.09.029

Cao, C., Yang, S., and Zhou, Z. (2020). The Potential Application of Cordyceps in Metabolic-Related Disorders. *Phytother. Res.* 34, 295–305. doi:10.1002/trpr.6536

Cao, X., Zhang, P., and Yang, J. (2007). Efficacy of Jinshuibao Combined with Valsartan in the Treatment of Early Type 2 Diabetic Nephropathy. *Chin. J. New Drugs* 16, 1303–1306.

Chang, Y., Hsu, W. H., Lu, W. J., Jayakumar, T., Liao, J. C., Lin, M. J., et al. (2015). Inhibitory Mechanisms of CME-1, a Novel Polysaccharide from the Mycelia of Cordyceps Sinensis, in Platelet Activation. *Curr. Pharm. Biotechnol.* 16, 451–461. doi:10.2174/1879201016666150303152237

Chen, G., and Goeddel, D. V. (2002). TNF-R1 Signaling: a Beautiful Pathway. *Science* 296, 1634–1635. doi:10.1126/science.1071924

Chen, P. X., Wang, S., Nie, S., and Marcone, M. (2013). Properties of Cordyceps Sinensis: A Review. *J. Funct. Foods* 5, 550–569. doi:10.1016/j.jff.2013.01.034

Chen, W., Zhang, W., Shen, W., and Wang, K. (2010). Effects of the Acid Polysaccharide Fraction Isolated from a Cultivated Cordyceps Sinensis on Macrophages *In Vitro*. *Cell. Immunol.* 262, 69–74. doi:10.1016/j.cellimm.2010.01.001

Coward, R. J., Welch, G. I., Yang, J., Tasman, C., Lennox, R., Koziell, A., et al. (2005). The Human Glomerular Podocyte Is a Novel Target for Insulin Action. *Diabetes* 54, 3095–3102. doi:10.23736/diabetes.54.11.3095

Di Vincenzo, A., Tana, C., El Hadi, H., Pagano, C., Vettor, R., and Rossato, M. (2019). Antioxidant, Anti-inflammatory, and Metabolic Properties of Tocopherols and Tocotrienols: Clinical Implications for Vitamin E Supplementation in Diabetic Kidney Disease. *Int. J. Mol. Sci.* 20, 5101. doi:10.3390/ijms20205101

Dong, C., and Yao, Y. (2012). Isolation, Characterization of Melanin Derived from Ophiocordyceps Sinensis, an Entomogenous Fungus Endemic to the Tibetan Plateau. *J. Biosci. Bioeng.* 113, 474–479. doi:10.1016/j.jbiosc.2011.12.001

Dong, C. H., and Yao, Y. J. (2008). *In Vitro* evaluation of Antioxidant Activities of Aqueous Extracts from Natural and Cultured Mycelia of Cordyceps Sinensis. *Leb. Wiss Technol.* 41, 669–677. doi:10.1016/j.jwet.2007.05.002

Dong, Z., Sun, Y., Wei, G., Li, S., and Zhao, Z. (2019). A Nucleoside/Nucleobase-Rich Extract from Cordyceps Sinensis Inhibits the Epithelial-Mesenchymal Transition and Protects against Renal Fibrosis in Diabetic Nephropathy. *Molecules* 24, 4119. doi:10.3390/molecules24224119

Du, F., Li, S., Wang, T., Zhang, H. Y., Zong, Z. H., Du, X. Z., et al. (2015). Cordyceps Sinensis Attenuates Renal Fibrosis and Suppresses BAG3 Induction in Obstructed Rat Kidney. *Am. J. Transl. Res.* 7, 932–940.

Eker, M. (2014). The Growing Use of Herbal Medicines: Issues Relating to Adverse Reactions and Challenges in Monitoring Safety. *Front. Pharmacol.* 4, 177. doi:10.3389/fphar.2013.00177

El Zahraa Z El Ashry, F., Mahmoud, M. F., El Maraghy, N. N., and Ahmed, A. F. (2012). Effect of Cordyceps Sinensis and Taurine Either Alone or in Combination on Streptozotocin Induced Diabetes. *Food Chem. Toxicol.* 50, 1159–1165. doi:10.1016/j.fct.2011.12.020

Fitchett, D. (2019). A Safety Update on Sodium Glucose Co-transporter 2 Inhibitors. *Diabetes Obes. Metab.* 21, 34–42. doi:10.1111/dom.13611

Glassock, R. J., Warmock, D. G., and Delaney, P. (2017). The Global Burden of Chronic Kidney Disease: Estimates, Variability and Pitfalls. *Nat. Rev. Nephrol.* 13, 104–114. doi:10.1038/nrneph.2016.163
Tang, R., Zhou, Q., Shu, J., Tang, T., Ao, X., Peng, W., et al. (2009). Effect of Cordyceps Sinensis Extract on Klotho Expression and Apoptosis in Renal Tubular Epithelial Cells Induced by Angiotensin II. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 34, 300–305.

Tang, S. C. W., and Yiu, W. H. (2020). Innate Immunity in Diabetic Kidney Disease. *Nat. Rev. Nephrol.* 16, 206–222. doi:10.1038/s41581-019-0234-4

Tigl, H., and Moschen, A. R. (2006). Adipocytokines: Mediators Linking Adipose Tissue, Inflammation and Immunity. *Nat. Rev. Immunol.* 6, 772–783. doi:10.1038/nri1937

Tomáš, E., Lin, Y. S., Dagher, Z., Saha, A., Luo, Z., Idy, O., et al. (2002). Hyperglycemia and Insulin Resistance: Possible Mechanisms. *Ann. N Y. Acad. Sci.* 967, 43–51. doi:10.1111/j.1749-6632.2002.tb04262.x

Tuli, H. S., Sandhu, S. S., and Sharma, A. K. (2014). Pharmacological and Therapeutic Potential of Cordyceps with Special Reference to Cordyceps. *J. Biotech.* 4, 1–12. doi:10.12580/jbt.2013-015-0121-9

Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., et al. (2014). Diabetic Nephropathy. *Kidney Int.* 83, 286–297. doi:10.1038/s41581-013-0073-6

Wada, J., and Makino, H. (2013). Inflammation and the Pathogenesis of Diabetic Nephropathy. *Clin. Sci. (Lond)* 124, 139–152. doi:10.1042/CS2012198

Wang, C., Hou, X. X., Rui, H. L., Li, L. J., Zhao, J., Yang, M., et al. (2018). Cordyceps Sinensis Polysaccharide Inhibits PDGF-BB-Induced Inflammation and Immunity. *Antioxid. Redox Signal* 33, 415–454. doi:10.1089/ars.2020.8047

Wang, W., and Qi, J. (2018). Clinical Study of Zhiling Capsule Combined with Telmisartan in Treatment of Early Diabetic Nephropathy. *J. Diabetes Res.* 2018, 1–9. doi:10.1155/2018/6390418

Wang, Y., Hu, N., Pan, Y., Zhou, L., and Zhou, X. (2007). Isolation and Characterization of a Mannoglucom from Edible Cordyceps Sinensis Mycelium. *Carbohydr. Res.* 342, 870–875. doi:10.1016/j.carres.2007.10.005

Xiao, L., Ge, Y., Sun, L., Xu, X., Xie, P., Zhan, M., et al. (2012). Cordycepin Inhibits Albumin-Induced Epithelial-Mesenchymal Transition of Renal Tubular Epithelial Cells by Reducing Reactive Oxygen Species Production. *Free Radic. Bio. Med.* 46, 174–183. doi:10.1016/j.freeradbiomed.2012.07.031

Xing, L., Guo, H., Meng, S., Zhu, B., Fang, J., Huang, J., et al. (2021). Klotho Ameliorates Diabetic Nephropathy by Activating Nrf2 Signaling Pathway in Podocytes. *Biochem. Biophys. Res. Commun.* 534, 450–456. doi:10.1016/j.bbrc.2020.11.061

Xu, B., H., Sheng, J., You, Y. K., Huang, X. R., Ma, R. C. W., Wang, Q., et al. (2020). Deletion of Smad3 Prevents Renal Fibrosis and Inflammation in Type 2 Diabetic Nephropathy. *Metabolism* 103, 154013. doi:10.1016/j.metabol.2019.154013

Yalin, W., Ishourd, O., Cuirong, S., and Yuanjiang, P. (2005). Structure Analysis and Antitumor Activity of (1→3)Beta-D-Glucans (Cordyglucans) from the Mycelia of Cordyceps Sinensis. *Planta Med.* 71, 381–384. doi:10.1055/s-2005-864111

Yan, J. K., Wang, W. Q., and Wu, Y. J. (2014). Recent Advances in Cordyceps Sinensis Polysaccharides: Mycelial Fermentation, Isolation, Structure, and Bioactivities: A Review. *J. Funct. Foods* 4, 33–47. doi:10.1016/j.jff.2013.11.024

Yan, T., Nian, T., Li, F., He, B., Jia, Y., Bi, K., et al. (2020). Salidroside From Rhodiola Wallichiana var. Cholaensis Reverses Insulin Resistance and Stimulates the GLP-1 Stimulation by Alleviating ROS-Mediated Activation of MAPKs Signaling Pathway and Mitigating Apoptosis. *J. Food Biochem.* 44, e13446. doi:10.1111/jbfc.13446

Yang, L. Y., Huang, J. W., Hsieh, H. G., and Lin, C. Y. (2003). H1-A Extracted from Cordyceps Sinensis Suppresses the Proliferation of Human Mesangial Cells and Promotes Apoptosis, Probably by Inhibiting the Tyrosine Phosphorylation of Bcl-2 and Bcl-XL. *J. Lab. Clin. Med.* 141, 74–83. doi:10.1067/mlc.2003.6

Yang, P., Zhao, X. C., and Zhang, Y. W. (2018). Comparison and Review on Specifications of Fermented Cordyceps Sinensis Products. *Zhongguo Zhang Yao Za Zhi* 43, 463–468. doi:10.19540/j.cnki.cjcmm.20171012.001

Yin, M., Zhang, Y., and Li, H. (2019). Advances in Research on Immunoregulation of Macrophages by Plant Polysaccharides. *Front. Immunol.* 10, 145. doi:10.3389/fimmu.2019.00145

Yoon, S. Y., Park, S. J., and Park, Y. J. (2018). The Anticancer Properties of Cordycepin and Their Underlying Mechanisms. *Int. J. Mol. Sci.* 19, 3027. doi:10.3390/ijms19103027

Yu, H. M., Wang, B. S., Huang, S. C., and Duh, P. D. (2006). Comparison of Protective Effects between Cultured Cordyceps Militaris and Natural Cordyceps Sinensis against Oxidative Damage. *J. Agric. Food Chem.* 54, 3132–3138. doi:10.1021/jf051311w

Yue, K., Ye, M., Zhou, S., Sun, W., and Lin, X. (2013). The Genus Cordyceps: a Chemical and Pharmacological Review. *J. Pharm. Pharmacol.* 65, 474–493. doi:10.1111/j.1354-6805.2012.01601.x

Zatz, R., Dunn, B. R., Meyer, T. W., Anderson, S., Remkne, H. G., and Brenner, B. M. (1986). Prevention of Diabetic Glomerulopathy by Pharmacological Amelioration of Glomerular Capillary Hypertension. *J. Clin. Invest.* 77, 1925–1930. doi:10.1172/JCI12521

Zhang, G., Huang, Y., Bian, Y., Wong, J. H., Ng, T. B., and Wang, H. (2006). Hypoglycemic Activity of the Fungi Cordyceps Militaris, Cordyceps Sinensis, Tricholoma Mongolicum, and Omphalia Lapidescens in Streptozotocin-Induced Diabetic Rats. *Appl. Microbiol. Biotecnol.* 72, 1152–1160. doi:10.1007/s00253-006-0411-9

Zhang, H., Li, Y., Mi, J., Zhang, M., Wang, Y., Jiang, Z., et al. (2017). GC-MS Profiling of Volatile Components in Different Fermentation Products of Cordyceps Sinensis Mycelia. *Molecules* 22, 1800. doi:10.3390/molecules22101800

Zhang, P., Xiao, X., Li, Y., and Lin, R. (2009). Chemical Analysis of Nucleosides and Alkalines Components in Five Preparations of Fermental Cordyceps. *Chin. J. Pharm. Analysis.* 889.

Zhang, W., Yang, J., Chen, J., Hou, Y., and Han, X. (2005a). Immumodulator and Antitumour Effects of an Exopolysaccharide Fraction from Cultivated
Cordyceps Sinensis (Chinese Caterpillar Fungus) on Tumour-Bearing Mice. Biotechnol. Appl. Biochem. 42, 9–15. doi:10.1042/BA20040183
Zhang, Y., Handy, D. E., and Loscalzo, J. (2005b). Adenosine-dependent Induction of Glutathione Peroxidase 1 in Human Primary Endothelial Cells and Protection against Oxidative Stress. Circ. Res. 96, 831–837. doi:10.1161/01.RES.0000164401.21929.CF
Zhou, L., Wang, S., Hao, Q., Kang, L., Kang, C., Yang, J., et al. (2018). Bioaccessibility and Risk Assessment of Heavy Metals, and Analysis of Arsenic Speciation in Cordyceps Sinensis. Chin. Med. 13, 40. doi:10.1186/s13020-018-0196-7
Zhu, J. S., Halpern, G. M., and Jones, K. (1998). The Scientific Rediscovery of a Precious Ancient Chinese Herbal Regimen: Cordyceps Sinensis: Part II. J. Altern. Complement. Med. 4, 429–457. doi:10.1089/acm.1998.4.429
Zhu, L., Fu, X., Chen, X., Han, X., and Dong, P. (2017). M2 Macrophages Induce EMT through the TGF-β/Smad2 Signaling Pathway. Cell. Biol. Int. 41, 960–968. doi:10.1002/cbin.10788

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Liu, Gao, Zhou, Yu, Li and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.